Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript

Nov 4, 2025 / 01:00 PM GMT

Release Date Price: €9.31 (-5.58%)

Transcript 10-Q8-K

Key Points

Positve

Ocular Therapeutix Inc (OCUL) has reached its target randomization of 555 subjects for the Solar trial, indicating strong execution and enthusiasm from investigators.
The company is pursuing a broad diabetic retinopathy label that encompasses both NPDR and DME, potentially capturing the full spectrum of diabetic eye disease with a single registrational program.
OCUL has a strong financial position with approximately $345 million in cash, not including $445 million from recent equity financing, providing a cash runway into 2028.
The company is strategically positioned to redefine the retina market through a triad of superiority, market expansion, and immediate adaptability.
OCUL's Helios program is designed with a novel ordinal endpoint, increasing statistical power and providing a higher probability of success compared to traditional endpoints.

Negative

OCUL is not yet in labeling discussions with the FDA, which introduces uncertainty regarding the final approval and market entry timeline.
The company faces pricing pressures and a commoditized landscape in the anti-VEGF market, which could impact profitability.
There is a risk of higher placebo effects in the Helios trials due to patient variability, which could affect the trial outcomes.
The success of the Helios trials is contingent on the acceptance of the novel ordinal endpoint by regulatory bodies, which is not guaranteed.
OCUL's strategy relies heavily on achieving a superiority label, which, if not obtained, could impact the company's competitive positioning.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OCUL.OQ - Ocular Therapeutix Inc
Q3 2025 Ocular Therapeutix Inc Earnings Call
Nov 04, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Ocular Therapeutics 3rd quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode.

After the prepared remarks, we will conduct a question-and-answer session. To ask a question, please press 1. As a reminder, this conference is being recorded and will be available for replay on the investor relations section of the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Lil Satter Jr. Please go ahead, Mr. Slattery.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.